Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 325 of 2026 entries
View as:

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00811993 Org: User:
Start: 02/28/09 End: 12/31/12 Due: 12/31/13

Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection

Phase: N/A Priority: Normal
NCT ID: NCT01297127 Org: User:
Start: 08/31/10 End: 09/30/13 Due: 09/30/14

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04774718 Org: User:
Start: 09/14/21 End: 02/28/32 Due: 02/28/33

A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05954910 Org: User:
Start: 08/25/23 End: 05/31/27 Due: 05/31/28

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

Phase: N/A Priority: Normal
NCT ID: NCT01750697 Org: User:
Start: 05/23/13 End: 05/10/18 Due: 05/10/19

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03674112 Org: User:
Start: 12/19/18 End: 10/12/22 Due: 10/12/23

An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)

Phase: N/A Priority: Normal
NCT ID: NCT01224093 Org: User:
Start: 10/31/10 End: 02/28/14 Due: 02/28/15

A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02694718 Org: User:
Start: 03/31/05 End: 11/30/06 Due: 11/30/07

A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)

Phase: N/A Priority: Normal
NCT ID: NCT02564614 Org: User:
Start: 05/02/16 End: 01/22/18 Due: 01/22/19

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Phase: N/A Priority: Normal
NCT ID: NCT02073279 Org: User:
Start: 08/05/14 End: 01/31/22 Due: 01/31/23

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00652366 Org: User:
Start: 05/31/08 End: 02/29/12 Due: 02/28/13

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HbeAg-negative Chronic Hepatitis B (Perseas)

Phase: N/A Priority: Normal
NCT ID: NCT01283074 Org: User:
Start: 05/31/09 End: 11/30/12 Due: 11/30/13

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04294810 Org: User:
Start: 03/04/20 End: 12/31/25 Due: 12/31/26

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03533283 Org: User:
Start: 05/08/18 End: 10/16/26 Due: 10/16/27

An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01319877 Org: User:
Start: 03/31/11 End: 03/31/15 Due: 03/31/16

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT01730508 Org: User:
Start: 11/20/12 End: 06/25/17 Due: 06/25/18

A Study to Compare Two Anti-HIV Drug Combinations

Phase: N/A Priority: Normal
NCT ID: NCT00002447 Org: User:
Start: 10/31/99 End: - Due: -

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

Phase: N/A Priority: Normal
NCT ID: NCT00754988 Org: User:
Start: 10/31/08 End: 03/31/11 Due: 03/31/12

A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01433575 Org: User:
Start: 09/30/11 End: 11/30/11 Due: 11/30/12

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00909597 Org: User:
Start: 05/31/09 End: 11/30/10 Due: 11/30/11

A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.

Phase: N/A Priority: Normal
NCT ID: NCT00551291 Org: User:
Start: 08/31/07 End: 06/30/09 Due: 06/30/10

A Study on The Effect of Multiple Doses of Activated Charcoal on The Pharmacokinetics of a Single Dose of RO4995819

Phase: N/A Priority: Normal
NCT ID: NCT01409369 Org: User:
Start: 08/31/11 End: 02/29/12 Due: 02/28/13

A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Metformin

Phase: N/A Priority: Normal
NCT ID: NCT01951183 Org: User:
Start: 12/31/13 End: 12/31/13 Due: 12/31/14

An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)

Phase: N/A Priority: Normal
NCT ID: NCT01974271 Org: User:
Start: 01/31/14 End: 04/30/15 Due: 04/30/16

A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT02892318 Org: User:
Start: 10/31/16 End: 12/12/19 Due: 12/12/20